Chronic Obstructive Pulmonary Disease News and Research RSS Feed - Chronic Obstructive Pulmonary Disease News and Research

The World Health Organisation (WHO) has described Chronic Obstructive Pulmonary Disorder (COPD) as a global epidemic; an estimated 210 million people have COPD worldwide and more than 3 million people died of the condition in 2005, which is equal to 5% of all deaths globally that year. Total deaths from COPD are projected to increase by more than 30% in the next 10 years without interventions to cut risks, particularly exposure to tobacco smoke.
Andor's Komet software used to automatically score modified 3D 'Comet' assay results

Andor's Komet software used to automatically score modified 3D 'Comet' assay results

With cancer rates rising worldwide, and Cancer Research UK predicting that the lifetime risk of cancer will reach 50% by 2027, the need for early diagnosis is overwhelming. Now, a British research group has published details of a simple empirical test to detect any early-stage cancer, relying on Andor's Komet software to automatically score the modified 3D 'Comet' assay results. [More]
Disease-associated malnutrition imposes economic burden on society

Disease-associated malnutrition imposes economic burden on society

Even in food-abundant industrialized countries like the U.S., an alarming number of people, particularly seniors, are in a state of diseased-associated malnutrition. Because of the impact on patient health, disease-associated malnutrition imposes a significant economic burden on society of $157 billion per year, according to new research published in a supplemental issue of the Journal of Parenteral and Enteral Nutrition and supported by Abbott. [More]
U-M startup company Imbio gets FDA approval to market Lung Density Analysis for COPD

U-M startup company Imbio gets FDA approval to market Lung Density Analysis for COPD

A technology that started in a University of Michigan Medical School lab may soon help lung disease patients around the world breathe a little easier, by helping their doctors make a clearer diagnosis and more individualized treatment plan. [More]
Apellis Pharmaceuticals completes $33M private placement of Series C Preferred Stock

Apellis Pharmaceuticals completes $33M private placement of Series C Preferred Stock

Apellis Pharmaceuticals, Inc., a leading biotechnology company applying immunotherapy to autoimmune disease, today announced that it has completed a $33M private placement of its Series C Preferred Stock. [More]
Clementia's palovarotene receives FDA Fast Track designation for FOP treatment

Clementia's palovarotene receives FDA Fast Track designation for FOP treatment

Clementia Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation to palovarotene, which is being developed for the treatment of fibrodysplasia ossificans progressiva (FOP). [More]
Persistent eosinophilia common in COPD

Persistent eosinophilia common in COPD

More than one-third of patients with chronic obstructive pulmonary disease have persistent eosinophilia, researchers report in the European Respiratory Journal. [More]
Better evidence needed for relationship between exercise and COPD

Better evidence needed for relationship between exercise and COPD

Researchers call for high-quality studies investigating the relationship between physical activity and chronic obstructive pulmonary disease after their systematic review found the level of evidence to be poor. [More]
Study shows effectiveness of VolitionRx’s NuQ test in detecting lung cancer in blood and sputum

Study shows effectiveness of VolitionRx’s NuQ test in detecting lung cancer in blood and sputum

VolitionRx Limited, a life sciences company focused on developing diagnostic tests for cancer and other conditions, today announced that data from its pilot lung cancer study will be presented at the Science for Business BioWin Day 2014, being held November 26, 2014 in Louvain-la-Neuve, Belgium. [More]
Clementia gets Orphan Medicinal Product Designation from EMA for palovarotene

Clementia gets Orphan Medicinal Product Designation from EMA for palovarotene

Clementia Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation for palovarotene, the company's lead product candidate, for the treatment of fibrodysplasia ossificans progressiva (FOP). [More]
Apellis Pharmaceuticals signs agreement to acquire Potentia Pharmaceuticals

Apellis Pharmaceuticals signs agreement to acquire Potentia Pharmaceuticals

Apellis Pharmaceuticals announced today that it entered into an agreement to acquire Potentia Pharmaceuticals. [More]
Nutrition treatment for older COPD patients shows better outcomes

Nutrition treatment for older COPD patients shows better outcomes

People aged 65 and older, who were being treated for chronic obstructive pulmonary disease (COPD) in the hospital and received nutrition treatment (oral nutrition supplements) had reduced lengths of stay, hospital costs and chances of returning to the hospital within 30-days, according to a study published in CHEST. [More]
University at Buffalo researchers receive $500,000 grant to study IED-induced vision loss

University at Buffalo researchers receive $500,000 grant to study IED-induced vision loss

It's well known that battlefield explosions can cause hearing loss, but veterans may be surprised to learn that their vision may also suffer — sometimes weeks or months after combat exposure. [More]
Community pharmacies can help identify COPD at early stage, save £264 million

Community pharmacies can help identify COPD at early stage, save £264 million

Using community pharmacies to identify undiagnosed cases of chronic obstructive pulmonary disease (COPD) at an early stage could save £264 million a year according to new research from the University of East Anglia. [More]
Studies evaluate traditional management of heart attack patients after discharge from hospital

Studies evaluate traditional management of heart attack patients after discharge from hospital

Beta-blockers have been a cornerstone in the treatment of heart attack survivors for more than a quarter of a century. However, many of the data predate contemporary medical therapy such as reperfusion, statins, and antiplatelet agents, and recent data have called the role of beta-blockers into question. [More]
New program aims to educate COPD patients on how to manage their disease

New program aims to educate COPD patients on how to manage their disease

The American Thoracic Society today announced a new program, produced with support from Sunovion Pharmaceuticals Inc., to provide materials to educate patients with chronic obstructive pulmonary disease (COPD) about this progressive lung disease and how it can be managed. [More]
LSTM receives research grants to develop Experimental Human Pneumococcal Carriage model

LSTM receives research grants to develop Experimental Human Pneumococcal Carriage model

Respiratory specialists at Liverpool School Tropical Medicine (LSTM) have been awarded two substantial research grants to further develop and utilise their Experimental Human Pneumococcal Carriage (EHPC) model. [More]
LSTM awarded research grants to develop Experimental Human Pneumococcal Carriage model

LSTM awarded research grants to develop Experimental Human Pneumococcal Carriage model

Respiratory specialists at Liverpool School Tropical Medicine have been awarded two substantial research grants to further develop and utilise their Experimental Human Pneumococcal Carriage (EHPC) model. [More]
New algorithm could help determine how to treat patients having difficulty breathing

New algorithm could help determine how to treat patients having difficulty breathing

Paramedics respond to a 911 call to find an elderly patient who's having difficulty breathing. Anxious and disoriented, the patient has trouble remembering all the medications he's taking, and with his shortness of breath, speaking is difficult. Is he suffering from acute emphysema or heart failure? The symptoms look the same, but initiating the wrong treatment regimen will increase the patient's risk of severe complications. [More]
Researchers make significant advancement in early diagnosis of invasive cancers

Researchers make significant advancement in early diagnosis of invasive cancers

A team of researchers from Inserm led by Paul Hofman (Inserm Unit 1081/University of Nice) has just made a significant advance in the area of early diagnosis of invasive cancers. In a study which has just been published in the journal PLOS ONE, the team shows that it is possible to detect, in patients at risk of developing lung cancer, early signs, in the form of circulating cancer cells, several months, and in some cases several years, before the cancer becomes detectable by CT scanning. [More]
New policy targeting hospital readmissions for COPD may hurt vulnerable patients, say experts

New policy targeting hospital readmissions for COPD may hurt vulnerable patients, say experts

Last week, the federal government revealed that it will fine more than 2,600 hospitals in the coming year, because too many Medicare patients treated at these hospitals are ending up back in the hospital within 30 days of going home. Two new conditions have been added in this round of penalties: elective hip and knee replacement and chronic lung disease. [More]